FDA Approves First RNA-Targeted Treatment for Rare Disease
FDA Greenlights Dawnzera: A Groundbreaking RNA-Targeted Treatment for Hereditary Angioedema The FDA has recently given its stamp of approval to Dawnzera (donidalorsen). This marks a significant milestone as it is…
